13^th International Conference on COPD and Lung Health November 28-29, 2024 London, UK

The “13th International Conference on COPD and Lung Health” Conference will take place from November 28-29, 2024, in London, UK following the theme Possible innovative ways to Cure and Prevent COPD. It encompasses a wide range of activities, including lectures, keynote, oral and poster presentations, exhibitions, panel discussions, and a wealth of knowledge-sharing opportunities. This year's agenda offers you the chance to take part in or organize a Workshop in addition to innovative presentations and discussions.

COPD Congress 2024 is available in both In-person and Online formats. We feel that your choice will allow for widespread engagement.

The major goal of COPD Congress 2024  is to bring together Medical experts, Pulmonologists, Endocrinologists, Embryologists, Endoscopic Surgeons, Reproductive Endocrinologists, Gynecological Oncologists, Researchers, Dermatologists, Professors, Doctors, Renowned speakers, Educationalists, and Students, and members of all COPD, Lung Health and Respiratory Associations and Universities to exchange ideas and to provide them with a forum on which to exchange knowledge and discuss recent developments in the field of COPD, of COPD, Lung Health and Respiratory Care. The new forms of innovations and research are encouraged and provide an opportunity to the people who are attending the conference. It allows delegates to have issues addressed on COPD, Lung Health, and Respiratory by recognized specialists who are up to date with the latest developments in the respective field and provide information on new techniques and technologies. You can share your research findings and gain recognition through certificates awarded by our esteemed world-class organizing committee.

Featured in COPD Congress 2024:

• Workshop
• Keynote & Plenary sessions
• Young researcher’s forum
• Symposium
• Exhibitor booths
• Separate room for B2B meetings
• Research excellence award
• Best poster competition
• Young Scientist Award

Abstract Submission:

Speakers from all over the world can submit their abstracts, research papers, case studies, and posters by choosing a topic from the “Call for Abstract” or your area of research interest.

Abstract Submission URL: https://copd.healthconferences.org/abstract-submission.php

Abstract Submission Guidelines:

• Abstract length not exceed 300 words.
•  The title should be in sentence case.
•   Mention the full name of the author and co-authors (if any) along with affiliation.
•   It should contain a short biography of the author (limited to 100 words) along with the photograph.
• All the abstracts will be reviewed by the scientific committee members and you will get an email within 24-48 hours after submission of your abstract.
•  All the accepted abstracts will be published in the conference proceedings in the respective Journal.

Registration:

COPD Congress 2024 will be an excellent arena for debating novel discoveries and concepts. Attendees' curiosity in the field of COPD, Lung Health and Respiratory will be piqued by the two-day session. It also makes it easier to access possibilities for ongoing education and top-notch content delivered by keynote speakers. For attendees, Doctors, Presenters, Physicians, Scientists, Educationalists, Students, Academicians, Sponsors, Exhibitors, and Groups, COPD Congress 2024 offers hotel packages and affordable registration and also provides Special registration for Webinar. Anyone can register for this conference using the choices available on the registration page

Registration Details URL: https://copd.healthconferences.org/registration.php

This is your best chance to get in front of the biggest group of people who are involved in the COPD, Lung Health and Respiratory Care community, since we have members from all over the world who are interested in learning about COPD care, Lung Health treatment and its advancements. The conference's characteristics include internationally recognized speakers, the most recent methods, discoveries, and breakthroughs in Health Care, COPD), Lung Health, Pulmonary Rehabilitation, Chronic Respiratory Diseases, Asthma-COPD Overlap (ACOS), Respiratory Infections, Pulmonary Function Tests (PFT), Inhaler Techniques, Smoking Cessation, Lung Inflammation, Emphysema, Bronchitis, Respiratory Therapy, Pulmonary Hypertension. People are searching for the most innovative treatments for COPD, Lung Health, diseases, and other ails all across the world.

At this two-day conference, present papers, disseminate information, network with established and upcoming scientists, make a splash with novel discoveries and therapeutic approaches and establish your name in the field.

• Opportunity to attend the presentations delivered by Eminent Scientists from all over the world
• Discuss your ideas and views with pioneers in the fields of COPD, Lung Health, Respiratory and Pulmonology
• Be a part of the interactive debates, plenary sessions and discussions about the current issues in the area of COPD and Lung Health and come to a consensus using evidence-based expert opinion
• It achieves the wide meet for key symposiums, workshops, and gives an edge work for understudies to have a sharp thought and gather great information.
• Pulmonologists, Respiratory Therapists, Primary Care Physicians, and Pulmonary Rehabilitation Specialists who work with patients suffering from Chronic Obstructive Pulmonary Disease (COPD) can receive credit for their efforts.
• Accepted abstracts will be published in the Journal of Lung Diseases & Treatment

• Pulmonologists
• Cardiologists
• Scientists
• Physicians/Consultants/ General Practitioners
• Directors/Managers
• Pathologists
• Presidents & Vice Presidents/ Directors / Administrators
• Business Entrepreneurs
• Pulmonology Pharma Companies
• COPD Associations/ Societies
• Training Institutes
• Young Researchers
• Medical Students
• Nurses
• Residents
• Medical Devices Companies
• Pulmonary Medicine and surgery related Companies

Track 1: Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease is one of the leading causes of disability and death worldwide. COPD exacerbation is usually treated with antibiotics, systemic corticosteroids, and inhaled bronchodilators. COPD exacerbation was treated repeatedly with standard therapy. Dynamic expiratory computed tomography of the chest was done, which revealed concomitant tracheomalacia. COPD and tracheomalacia may coexist during recurrent exacerbations of COPD, and delayed diagnosis can be associated with severe comorbidities. Ordering the appropriate imaging technique may aid in the correct diagnosis and facilitate appropriate management. COPD Conferences will survey the evolution of pulmonology.

Track 2: COPD Pathogenesis

Chronic obstructive pulmonary (COPD) disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Pathologic changes in COPD occur in the generous airways, the small bronchioles, and the lung parenchyma. The pathogenic mechanisms are not clear but are most likely diverse. Increased number of activated polymorph nuclear leukocytes and macrophages release elastases in a manner that cannot be counteracted effectively by antiproteases, emerge in lung desolation

• Chronic bronchitis
• Emphysema
• Refractory asthma

Track 3:Emphysema

Emphysema is a progressive and chronic lung disease that falls under the broader category of Chronic Obstructive Pulmonary Disease (COPD). It is characterized by the destruction of the air sacs (alveoli) in the lungs, leading to a loss of their elasticity. This loss of elasticity reduces the ability of the lungs to expand and contract efficiently, impairing normal airflow. Regular follow-ups with healthcare professionals are essential for monitoring the progression of the disease and adjusting the treatment plan accordingly.

• Alveolar Damage
• Shortness of Breath
• Chronic Cough
• Wheezing

Track 4:Spirometry

Spirometry is a diagnostic test measuring lung function by assessing the volume and flow of inhaled and exhaled air. This non-invasive procedure aids in diagnosing respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. During spirometry, a person inhales deeply and then exhales forcefully into a device called a spirometer. The results, including vital capacity and forced expiratory volume, help evaluate lung health, identify abnormalities, and guide treatment decisions. Spirometry is a valuable tool for monitoring respiratory diseases, assessing lung function impairment, and optimizing patient care.

Track 5: Chronic bronchitis

Chronic bronchitis is a type of chronic obstructive pulmonary disease (COPD), which is a group of progressive lung diseases that make it difficult to breathe. It is characterised by inflammation of the bronchial tubes, which are the air passages that carry air to the lungs. This inflammation leads to increased production of mucus and other changes in the bronchial tubes. Chronic bronchitis can significantly impact daily life and, if not managed, may contribute to the progression of COPD.

• Acute Bronchitis
• Allergic Bronchitis
• Reactive Airway Disease (RAD)
• Inflammation and Mucus Production

Track 6:Tobacco control

Tobacco control is a critical aspect of managing chronic obstructive pulmonary disease (COPD) because cigarette smoking is the leading cause of COPD. COPD encompasses conditions such as chronic bronchitis and emphysema, characterized by progressive airflow limitation and difficulty breathing. Controlling tobacco use is central to preventing and managing COPD. Multifaceted approaches that combine public health policies, clinical interventions, and community engagement are crucial for reducing the burden of COPD associated with tobacco smoking.

• Smoking Cessation
• Tobacco Control Policies
• Integrated Care
• Public Awareness Campaigns

Track 7: Lung cancer

Lung cancer is a malignancy that originates in the lung cells, typically caused by tobacco smoke. It is broadly classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Symptoms include persistent cough, chest pain, and shortness of breath. Diagnosis involves imaging tests and biopsies, with treatment options such as surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. Prevention includes smoking cessation and minimizing exposure to carcinogens. Ongoing research aims to enhance early detection and develop more effective treatments.

Track 8: Types of COPD

People with different kinds of COPD experience difficulty in breathing and shortness of breath. The two major infections that fall under the extent of COPD are: Chronic bronchitis, which involves a long-term cough with mucus, it is a long-term inflammation of the bronchi, which results in increased exhibition of mucus, as well as other changes. These changes may result in breathing problems, frequent infections, cough, disability, anxiety and depression. Emphysema which includes harms to the lungs over time. Emphysema is a chronic lung condition in which alveoli may be destroyed, narrowed, narrowed, stretched, and over-inflated. This can cause a reduction in respiratory volume and breathlessness. Harm to the air sacs is irreversible and brings about permanent "holes" in the lung tissue

Track 9: Drug Discovery of COPD

Chronic obstructive pulmonary disease is an expanding worldwide medical issue and cause of death. COPD mostly influencing small airway routes and lung parenchyma that prompts dynamic aviation route deterrent. COPD is a standout amongst the most widely recognized infections on the globe, and there is a global increase in generality, however there are no drugs available at present that halt the relentless progression of this disease. In any case, a superior perception of the cell and molecular mechanisms that are associated with the underlying inflammatory and destructive processes has uncovered a few new centres for which drugs are presently being developed, and the prospects for detection new medications are good.

Track 10: Effect of COVID-19 on Lungs

COVID-19 is a respiratory disease which causes a range of breathing issues, from mild to critical. Older adults and people who have other health conditions like heart disease, cancer and diabetes may have more significant symptoms when compared to others. Coronavirus can infect the upper or lower part of the respiratory zone and travels down the airways making the edge become irritated and inflamed. In some instances, the infection can reach all the way down into the alveoli. Respiratory inflammation can be notice on a chest X-ray or CT scan. Contemporary, convalescent plasma from a recovered patient is given by transfusion to a patient who is suffering from COVID-19. The donor antibodies may help the patient fight the illness, possibly shortening the reducing the severity of the disease

Track 11: Diagnosis and Treatment of COPD

The major test for diagnosing COPD is a lung function test is known as spirometer which involves the use of a machine called a spirometer that measures how much air you are able to move by taking a deep breathe in and out, and how rapidly you are able to do so. Arterial blood gas analysis is second important test in diagnosing COPD. This test measures how much oxygen and carbon dioxide are present in the blood. A high percentage of carbon dioxide in the blood can be an indication of badly functioning lungs.

The principal methods of treatment are pharmacotherapy and smoking cessation, while pulmonary rehabilitation, long-term oxygen therapy, and surgery may be considered in selected patients. Steroids, inhalers and antibiotics may be prescribed to treat various indications of COPD. Smoking stoppage is the most effective interference in stopping the progression of COPD, as well as increasing survival rate of persons suffering with COPD. Hence, smoking stoppage should be the main priority in the treatment of COPD

Track 12: Lung Transplantation

A lung transplant is a surgical procedure to replace a diseased lung with a healthy lung. It is used to improve the quality of life and prolong the lifespan in people affected with severe or advanced chronic lung cases. The surgery can be for one lung or for both. Lung transplants can be over on people of almost all ages from new born to adults up to age 65.

Track 13: Stages & Severity on Lung Diseases

There is no formal organizing system for pulmonary fibrosis. Physicians use different factors, like the ones listed below to describe the disease as mild, moderate, severe or very severe.

• Pulmonary Function Test or Lung function Test
• Six minute walk test
• A high resolution CT scan

Track 14:Lung Cancer: Screening, Diagnosis & Treatment

Lung cancer is a condition that causes cells to divide in the lungs uncontrollably which leads to the growth of tumours that reduce a person's ability to breathe. Symptoms of lung cancer involves appetite loss, changes to a person's voice, such as hoarseness, regular chest infections, such as bronchitis or pneumonia, lingering cough that may start to get worse, shortness of breath, unexplained headaches, weight loss and wheezing.

Early diagnosis of lung cancer: It can be lifesaving because lung cancer cells can travel to other parts of the body before a doctor detects them in the lungs. If metastasis has taken place, it makes treating the disease much more difficult.

Treatment for lung cancer: It is based on its location and stage, as well as the overall health of the individual. Possible treatments include

• Surgery
• Chemotherapy
• Radiation therapy and targeted therapy

Track 15: COPD and Air Pollution

Chronic Obstructive Pulmonary Disease (COPD) and Asthma are especially vulnerable to the obviously harmful effects of air pollutants. Air pollution can cause the increase of COPD and onset of asthma, increase the respiratory morbidity and mortality.

Air pollutants such as materials from the fuel combustion can cause inflammation in lungs and further impaired the decreased pulmonary function in COPD patients.

People especially those with COPD or asthma should be aware of the air quality and take excess measures.

Track 16: Cardio Pulmonary Disorders

Cardio Pulmonary Disorders are illustrating as the range of serious disorders that affects the heart and lungs. Cardiovascular disease is represent as any abnormal condition characterised heart or blood vessel dysfunction. Cardiovascular Disease (CVD) contains diseases affecting the Heart and blood vessels.

Track 17: Respiratory Failure and COPD Complications

Respiratory Failure occurs when lungs fail to do their job passing oxygen into your bloodstream and eliminate carbon dioxide. It is a complication of chronic obstructive pulmonary disease (COPD) and other severe respiratory disorders.

COPD prevents the lungs from working efficiently, which can lead to complications

Track 18: Respiratory Tract Infections

Respiratory Tract Infections are any infectious diseases of the upper and lower respiratory tract.

• Upper respiratory tract infection
• Lower respiratory tract infection
• Tuberculosis (TB)
• Influenza (Flu)

Upper Respiratory Tract Infection (sinuses and throat)

The infections are caused by virus. Upper respiratory tract (which starts at sinuses and ends at vocal chords) infection includes the common cold, laryngitis, pharyngitis/tonsillitis, acute rhinitis, acute rhinosinusitis and acute otitis media.

Lower Respiratory Tract Infection (airways and lungs)

Lower respiratory system begins at vocal chords and ends at lungs. Lower respiratory tract infections includes acute bronchitis, bronchiolitis, pneumonia and tracheitis. Lower respiratory tract infections tend to establish and can be severe.

Track 19:Respiratory and sleep Medicine

Sleep Medicine is a multidisciplinary field with contributions by practitioners and researchers from different disciplines. Pulmonary medicine has made important contributions to the field of sleep medicine for the past many years.

Patients suffering from COPD have sleep protests characterized by a longer time to fall asleep, more constant arousals and awakenings in sleep, and generalized insomnia. Sleep disturbance leads to be more severe as the disease advances and substantially reducing the patient’s quality of life.

Track 20: Prevention of COPD

Primary Prevention: Avoid exposure, Help fight for clean air, never start smoking or quit smoking, reduce your exposure to COPD causing irritants

Secondary Prevention: Vaccination and Physical activity

Track 21:Self-Management and Prevention of COPD

Self-Management arrangement in COPD includes quitting smoking, improving exercise and physical activity levels, proper nutrition, and medication adherence. It is concentrating on a system for the exacerbation, and enhanced communication between the patient and health care providers make good clinical sense. It is deliberated an integral components of chronic care model of disease management which involves health care organization, community resources, delivery system redesign, and clinical information systems.

It helps the patient to acquire knowledge and skills required to follow the medical therapies. An efficient review of self-management in COPD concluded that it reduces hospital admissions and has no adverse effects.

Track 22: Depression and Anxiety in COPD

Anxiety and depression are common in patients affected by the chronic obstructive pulmonary disease (COPD). The degree of lung function might not describe anxiety and depression. These are difficult to identify and deal with their symptoms often project with those of COPD. Also, increase the risk of re-hospitalization and mortality. Dyspnea and reduced act capacity are the mechanisms that lead to the symptoms of anxiety and depression associated with COPD. Pulmonary rehabilitation develops anxiety and depression in COPD

Track 23: Pediatric Pulmonology & Critical care

Pediatric Pulmonology is a medical speciality that deals with the diagnosis and treatment of diseases involving respiratory tract and it is a combination of both pulmonology and paediatrics. These are specially qualified in pulmonary pediatric diseases and conditions of chest.

Pediatric pulmonology and Critical Care is accomplished to caring for critically ill patients and patients with lung diseases- asthma, pneumonia, wheezing, bronchitis, COPD, cystic fibrosis. The division of pediatric pulmonary and critical care is consisted of a team of outstanding clinicians, scientists, and scholars dedicated to improve the lives of patients with serious lung disease and those who are critically ill.

Track 24: COPD-Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease is one of the leading causes of disability and death worldwide Chronic Obstructive Pulmonary Disease is a progressive disease that causes airflow blockage and problems related to breathing. It can cause coughing that produces large amounts of a slimy substance called mucus, wheezing, and shortness of breathe as well as chest tightness. Cigarette smoking is the main cause of COPD. Long-term exposure to various lung irritants such as air pollution, chemical fumes or dusts also contributes to COPD. A rare genetic situation called alpha-1 antitrypsin (AAT) deficiency can also lead to COPD. COPD cannot be cured but it can be treated to lower the chance of complications, and generally improve quality of life

Track 25: Pulmonary diseases

Pulmonary diseases encompass a diverse range of conditions affecting the respiratory system. These diseases compromise lung function, leading to symptoms like coughing, shortness of breath, and chest pain. Factors such as smoking, infections, genetics, and environmental exposures contribute to their development. Diagnosis involves medical history, imaging, and pulmonary function tests. Management includes medications, lifestyle adjustments, and, in severe cases, surgical interventions. Early detection and comprehensive care are vital to mitigate symptoms, improve quality of life, and address the global health impact of pulmonary diseases.

• Tuberculosis (TB)
• Pulmonary Hypertension
• Interstitial Lung Diseases
• Bronchiectasis

Track 26: Asthma and Allergy

Asthma is a severe chronic condition that affects the air ways. It involves inflammation that makes it difficult to breath inside the lungs. Asthma symptoms occur when the filling of the airways swell and therefore the muscles around them tighten. Mucus then fills the airways further reducing the amount of air produce an asthma “attack,” the coughing and tightness in your chest region that’s typical of asthma.There are Airflow obstruction, Bronchospasm, Nocturnal Asthma, Chronic Obstructive Airways Disease, Asthma diagnosis & Treatment

Allergy develops when a person’s body becomes sensitized to a specific essence or condition in which the immune system reacts abnormally to certain foreign essence. Atopy is the genetic bias to develop the allergic diseases. When atopic people are exposed to allergens they can improves an immune reaction that may leads to allergic inflammation.There are Food Allergy, Skin Allergy, Dust Allergy, Drug Allergy

Track 27:Pediatric Neonatal Care in COPD

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by airflow limitation and breathing difficulties, primarily caused by long-term exposure to irritants such as tobacco smoke. Ensuring optimal lung health from the neonatal stage is crucial in preventing long-term respiratory issues and improving overall quality of life. Neonatal care plays a vital role in shaping lung health, influencing the risk of developing COPD and other respiratory conditions later in life.

The Report Covers Chronic Obstructive Pulmonary Disease Treatment Market Trends and it is Segmented by Drug Class (Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs), Indication (Asthma and Chronic Obstructive Pulmonary Disease), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are Provided in terms of value in USD million for all the above segments.

Asthma and COPD Drugs Market Analysis

Asthma and COPD drugs market is expected to witness a CAGR of 4.6% during the forecast period.

COVID-19 had a significant impact on the growth of the market during the pandemic period. Chronic obstructive pulmonary disease (COPD) patients had an increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptors in small airways. An NCNI article published in March 2022, mentioned that COPD is associated with worse clinical outcomes from COVID-19. Also, according to a research study published in the Nature Journal in February 2021, in South Korea, among the COVID-19 infected patients who are 40 years and older, 3.1% had COPD; of these 7.1% received ICU care, and 5.7% received mechanical ventilation. Thus, the COVID-19 pandemic had a significant impact on the asthma and COPD drugs market.

Some of the factors that are driving the market growth include an increase in the incidence and prevalence of asthma and COPD, advanced therapeutic drugs, and a growing geriatric population.

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic lung disease that affects men and women worldwide. According to the NCBI article published in March 2022, the estimated pooled prevalence of COPD was 11.1% in South Asian countries in 2021. The report also mentioned that the prevalence of COPD was highest in North India (19.4%) and Bangladesh (13.5%). Moreover, the increasing geriatric population globally is boosting the market growth. According to the WHO data published in October 2022, the population aged 60 years and over will increase to 1.4 billion in 2030 and is expected to reach 2.1 billion by 2050. The UN report in 2022 mentioned that the share of the population aged 65 years or over is projected to rise from 10% in 2022 to 16% in 2050. As, the geriatric population is most prone to developing asthma conditions, the increase in the geriatric population is expected to contribute to the growth of the market.

In addition, technological advancements are anticipated to provide the market with lucrative opportunities. Limitations of traditional treatments, such as the late onset of action and low efficacy, are projected to encourage the development of novel targeted drugs, thereby boosting the market. For instance, in February 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a Phase III clinical trial to assess the efficacy and safety of itepekimab on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial was expected to be completed in July 2024.

The market players are adopting various strategies such as product launches, developments, collaborations, acquisitions, and expansions to increase their market shares. For instance, in June 2021, Valeo Pharma Inc. commercially launched the Enerzair Breezhaler and Atectura Breezhaler for the treatment of asthma patients in Canada. These products have demonstrated that they improve the level of control of asthma symptoms and better prevent related complications.

Thus, the factors such as an increase in the incidence and prevalence of asthma and COPD, advanced therapeutic drugs, and increasing product developments are expected to contribute to the growth of the market. However, factors such as stringent government regulations for product approvals and side effects associated with drugs are expected to impede market growth over the forecast period.

Asthma and COPD Drugs Market Trends

This section covers the major market trends shaping the Asthma & COPD Drugs Market according to our research experts:

The Asthma Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Asthma is considered one of the world's most common diseases affecting the population and a life-threatening condition affecting patients' regular breathing. It is a persistent condition that stretches and narrows the air passages of the lungs, causing constant assaults of breathlessness, bronchospasm, and reversible obstruction of airflow. Moreover, there is a large rise in the consumption of cigarettes, which contributes to asthma symptoms. In addition, the rise in industrialization has also contributed to an increase in the number of cases of asthma, which is expected to drive the growth of the studied segment.

The substantial increase in the prevalence and incidence of asthma has increased the patient population, increasing the demand for these drugs. According to the Australian Bureau of Statistics data 2021, over 2.7 million Australians had asthma in 2021. The data also mentioned that females were more likely to have asthma (12% compared to 9.4%). Enormous investments in the study of asthma drugs accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market.

For instance, in March 2021, GlaxoSmithKline PC, in collaboration with Iqvia Pty Ltd, initiated a Phase III clinical trial to evaluate the efficacy and safety of GSK3511294 (Depemokimab) in adult and adolescent patients with severe uncontrolled asthma. The trial was expected to be completed in October 2023. Similarly, in February 2021, AstraZeneca PLC, in collaboration with Amgen Inc., initiated a Phase I clinical trial to evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged 5 to 11 years with asthma. The trial was expected to be completed in September 2021. Thus, the aforementioned factors
such as an increase in the prevalence and incidence of asthma and rising product developments are expected to drive segment growth over the forecast period.

Types of participation

COPD Congress 2024, provides the participants with different modes or ways to participate under either Academic / Student / Business Category

1. Keynote speaker: 45-50 minutes
2. Speaker (oral presentation): 25-30 minutes (only one person can present)
3. Speaker (workshop): 45-50 minutes (more than 1 can present)
4. Speaker (special session): 45-50 minutes (more than 1 can present)
5. Speaker (symposium): more than 45 minutes (more than 1 can present)
6. Delegate (only registration): will have access to all the sessions with all the benefits of registration
7. Poster presenter:  can present a poster and enjoy the benefits of delegate
8. Remote attendance:  can participate via virtual mode or video presentation or e-poster presentation
9. Exhibitor: can exhibit his/her/their company’s products by booking exhibitor booths of different sizes
10. Media Partner
11. Sponsor
12. Collaborator

Advantages of Participating in our Conference

• Attendees will be certified with CPD credits with participation certification
• The Speaker and Abstract pages that Google creates on your profile under your name would give you global visibility.
• Our Library of Abstracts receives more than 30,000 visits per month and 50 thousand views, which brings scholars and speakers to our Conference.
• Interactive meetings will be provided, if you are coming with your research squad
• Meet and exchange ideas with many of thought leaders in the COPD, Lung Health and Respiratory Care field
• Young scientist award & Best Poster certificates
• Each conference attendee would have a different motivation for engaging in one-on-one discussions with distinguished speakers and recognized keynote speakers.
• At our Keynote presentations, you'll have the exceptional chance to hear what the world's foremost authorities on COPD and Respiratory Care are discovering.

Benefits of Participation for Speaker

• All accepted abstracts will be published in the respective Journals
• Attendees will be certified with CPD credits with participation certification
• Admiration for researchers' profiles on a global scale.
• Obtain points for your professional development.
• Discover the most recent cutting-edge analysis.
• Become lifelong friends through social and networking activities.
• An opportunity to promote one page through the distribution of abstract books and flyers, which eventually receive 1 million views and greatly enhance your research profile.
• Learn about new topics and studies that are unrelated to your primary subject of COPD and Lung Health field by making a transition outside of your field of interest.
• We've combined exceptional networking, education, and fun into one bundle.

Benefits of Participation for Delegate

• Increased knowledge and understanding for professional development.
• Attending conferences and webinars helps participants feel refreshed and energized.
• Your participation in our conference will support the development of a new approach and philosophy that can be used to improve business or industry results.
• Opportunities for COPD, Lung Health and Respiratory Care field scholars and practitioners to connect and share new perspectives at our conference.

Benefits of Participation for Sponsor

• The likelihood of new businesses would rise with exposure to the global marketplace.
• A chance to showcase your business's most cutting-edge innovations, products, or services to a large international audience.
• Lead generation will help our conference participants do more business.
• To draw energy from others who have a similar purpose and objective, it's always helpful to have a network of co-workers and associates. Building a successful firm takes a lot of time, effort, and drive.
• Conferences and Webinars on COPD and Lung Health offer chances for greater thought and reflection, which might help you, advance your business.
• Comparing the major organization's plans and advancing them.
• Get answers to your company's queries and difficulties at our conference from reliable people.

Benefits of Participation for Collaborators

• No other website has this many visits, making COPD Congress 2024 the finest platform for bringing attention to society.
• Establishing enduring peer ties.
• Your organization's logo, branding and marketing materials, promotional content, and the conference banner will all work together to add 40% more subscribers and members to your list.
• Your association will be greatly impacted by the visibility of our event to your company's placement in the Global Business forum.
• Your representatives can interact with important delegates to update their knowledge and comprehension of your organization and services.
• Information will be incorporated into COPD Congress 2024 advertising materials such as posters, brochures, pamphlets, and services that will be distributed to hospitals, universities, the general public, and researchers.

Visa Trip Advisor

Planning a trip to London, UK?? Attend our Meeting!!

Issue with VISA??

To support the participants in his/her VISA application process, we issue each participant with VISA support documents. The documents are as follows,

• The official letter of INVITATION
• The official letter of the abstract acceptance
• The receipt of the payment

Points to be noted:

• Visa  Letter (the official letter of invitation) will be issued only after you have successfully registered and paid for the conference
• Visa Letters can be issued only for the person accepted to attend the conference.

Please contact the Program Manager, Ms. Sophia Karl via annualsummit@conferencesinternational.org to arrange for a Visa Letter.

Kindly provide us with the following to provide you with VISA LETTERS

• Your name as appears on your passport
•  Your Passport Scan Copy (For passport number and Date of Birth)
•  And Abstract Acceptance letter for Presenters

One can make the payment through the following Payment Methods:

• Payment Gateway/Stripe
• Bank to Bank transfer

Having trouble in registration?

Please contact Ms. Sophia Karl via annualsummit@conferencesinternational.org.The team of COPD CONGRESS 2024 will provide you the INVOICE for the requested price with which he/she can make the Bank-to-Bank transfer.